Skip to content
The 340B program grew by 24% in 2023, according to new figures from the government’s Health Resources and Services Administration. Sales at discounted prices […]
Skyrocketing 340B program spending must prompt more hospital accountability Read More »
The 340B Program has grown exponentially as hospitals take advantage of the opportunity to profit from drug discounts while the low-income and uninsured patients
BIO tells Senators the 340B program needs reforms so it helps patients Read More »
Key legislation providing greater transparency and oversight into the 340B federal drug program moved forward in the U.S. House on May 25. The House
340B legislation advances in U.S. House Read More »
Pharmacy benefit managers (PBMs) and hospitals using the 340B program were in the crosshairs on May 17 as the House Energy & Commerce Health
E&C Health Subcommittee advances bills to bring transparency to PBMs and 340B Read More »
Questions regarding the significant profits made by the 340B Drug Pricing Program were raised before the United States Senate Committee on Health, Education, Labor,
Fund tracing shows that a reform of 340B is long overdue Read More »
In a move that will help the 340B pharmaceutical discount program get back on track, the U.S. Third Circuit Court of Appeals decided Monday
Federal court rules against HHS on 340B contract pharmacies Read More »
At 30-years old, the 340B program is buckling under its own weight and overdue for reform. With legal action, including a Supreme Court ruling,
The 30-year-old 340B drug discount program is due for reform Read More »
The federal 340B Drug Pricing Program is starting to get a great deal of attention—for all the wrong reasons. The program was started in
Hospitals and pharmacies profit as 340B drives up patients’ drug costs Read More »
America, for decades, has been the undisputed global leader when it comes to innovative drug development. But this leadership is now at risk. “We
BIO Coffee Chat: ORPHAN Cures Act key to fighting rare disease Read More »
State legislatures remain busy across the country—especially when it comes to healthcare policy. As Q1 wraps up and we move into the mid-year, the
Q1 roundup of state health policy impacting biotech Read More »
